ACTIVE

PALISEUL PHARMA

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

183,7 k €

+2.0% YoY

Gross margin

691,9 k €

+46.3% YoY

Equity

906,2 k €

+8.9% YoY

Workforce

3,6 ETP

+5.9% YoY

What does PALISEUL PHARMA do?

PALISEUL PHARMA is a Private limited company incorporated in 2005. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Paliseul. It employs on average 3,6 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0874.952.569

Incorporation

07/07/2005

Legal form

Private limited company

Registered office

Grand-Place 16
6850 Paliseul · WallonieSee on map

Contributed capital

6 200,00 €

Latest accounts

31/12/2025

Average workforce

3,6 ETP

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	691,9 k €	+46.3%	472,8 k €	+11.5%	424,1 k €	+2.7%	413 k €	+3.8%	397,9 k €	+7.4%	370,4 k €	+6.2%	348,9 k €	+6.0%	329,2 k €	+13.1%	291,2 k €	+6.0%	274,8 k €	+14.1%	240,9 k €	+31.2%	183,5 k €	-1.0%	185,3 k €	+33.4%	138,9 k €	-1.4%	140,9 k €	-9.4%	155,5 k €	-1.2%	157,4 k €	+28.3%	122,7 k €	-4.9%	128,9 k €	-29.3%	182,3 k €
EBITDA	429,6 k €	+65.6%	259,3 k €	+1.5%	255,6 k €	+9.1%	234,2 k €	+9.1%	214,7 k €	+1.6%	211,4 k €	+11.8%	189,2 k €	-16.9%	227,7 k €	+11.3%	204,6 k €	+4.9%	195 k €	+24.6%	156,4 k €	+61.9%	96,6 k €	+0.8%	95,8 k €	+59.2%	60,2 k €	-13.4%	69,5 k €	-21.4%	88,4 k €	-1.7%	89,9 k €	+32.6%	67,8 k €	-24.0%	89,2 k €	-19.7%	111,1 k €
Operating result	273,9 k €	+26.4%	216,8 k €	-9.5%	239,5 k €	+9.8%	218,2 k €	+13.4%	192,4 k €	+1.0%	190,5 k €	+13.5%	167,9 k €	-19.9%	209,5 k €	+12.6%	186,1 k €	+2.9%	180,8 k €	+63.4%	110,6 k €	+140%	46,1 k €	+8.9%	42,3 k €	+494%	7,1 k €	-58.8%	17,3 k €	-42.4%	30 k €	+8.8%	27,6 k €	+432%	5,2 k €	-81.8%	28,4 k €	+10.6%	25,7 k €
Net result	183,7 k €	+2.0%	180,2 k €	-5.2%	190 k €	+12.1%	169,5 k €	+13.1%	149,8 k €	-1.6%	152,3 k €	+27.4%	119,5 k €	-22.8%	154,8 k €	+25.9%	122,9 k €	-4.7%	129 k €	+65.3%	78 k €	+114%	36,5 k €	+26.5%	28,9 k €	+2100%	-1,4 k €	-134%	4,2 k €	-65.7%	12,2 k €	+28.7%	9,5 k €	+199%	-9,6 k €	-213%	8,5 k €	+1204%	-774 €
Balance sheet
Equity	906,2 k €	+8.9%	832,4 k €	+20.3%	692,2 k €	+23.1%	562,2 k €	+22.8%	457,8 k €	+4.5%	437,9 k €	+23.5%	354,6 k €	+39.0%	255,1 k €	+44.7%	176,3 k €	+36.3%	129,3 k €	+69.5%	76,3 k €	+28.8%	59,2 k €	+24.2%	47,7 k €	+65.6%	28,8 k €	-4.8%	30,3 k €	+16.1%	26,1 k €	+88.3%	13,8 k €	+219%	4,3 k €	-68.9%	14 k €	+158%	5,4 k €
Total assets	2,6 M €	-4.7%	2,8 M €	+134%	1,2 M €	+6.9%	1,1 M €	+1.5%	1,1 M €	+18.7%	914,9 k €	+14.8%	796,7 k €	+6.4%	748,5 k €	+29.6%	577,7 k €	-1.6%	587 k €	+3.4%	567,5 k €	+139%	237 k €	-16.7%	284,7 k €	-8.0%	309,3 k €	-13.7%	358,6 k €	-9.8%	397,5 k €	-12.0%	451,8 k €	-11.2%	509 k €	-13.2%	586,2 k €	-3.4%	607,1 k €
Cash	583 k €	+30.1%	448,2 k €	+64.8%	272 k €	+17.8%	230,9 k €	-27.1%	316,9 k €	+95.1%	162,4 k €	+51.8%	107 k €	-1.4%	108,4 k €	+289%	27,9 k €	-54.6%	61,4 k €	+10.2%	55,7 k €	+482%	9,6 k €	-17.4%	11,6 k €	-34.5%	17,7 k €	+87.1%	9,4 k €	+173%	3,5 k €	+230%	1 k €	-42.3%	1,8 k €	-94.4%	32,4 k €	+361%	7 k €
Debts	1,7 M €	-10.3%	1,9 M €	+296%	485,5 k €	-10.1%	539,7 k €	-14.0%	627,5 k €	+31.7%	476,5 k €	+7.9%	441,6 k €	-10.4%	493 k €	+22.9%	401,1 k €	-12.3%	457,3 k €	-6.8%	490,8 k €	+177%	177,4 k €	-24.9%	236,3 k €	-15.6%	280,1 k €	-14.5%	327,8 k €	-11.6%	370,7 k €	-15.2%	437,4 k €	-13.2%	504,2 k €	-11.9%	572,1 k €	-4.9%	601,6 k €
Other
Workforce	3,6 ETP	+5.9%	3,4 ETP	+3.0%	3,3 ETP	-5.7%	3,5 ETP	-22.2%	4,5 ETP	+4.7%	4,3 ETP	+2.4%	4,2 ETP	+31.3%	3,2 ETP	+68.4%	1,9 ETP	-5.0%	2,0 ETP	+5.3%	1,9 ETP	0.0%	1,9 ETP	-9.5%	2,1 ETP	+16.7%	1,8 ETP	+5.9%	1,7 ETP	0.0%	1,7 ETP	-5.6%	1,8 ETP	+5.9%	1,7 ETP	+13.3%	1,5 ETP	0.0%	1,5 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 1 M€ and 2,5 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 6 ended

Active mandates

PO²

Director · since 01 avril 2015 · 0598.929.369

Represented by Philippe ROBYN

Active

Ended mandates

PO²

Manager · since 01 avril 2015 · 0598.929.369

Represented by Philippe ROBYN

Ended

PO²

Manager · since 01 avril 2015 · 0598.929.369

Represented by Philippe ROBYN

Ended

Nadine VAN HEMMENS

Manager · since 05 juillet 2005

Ended

Nadine VANHEMMENS

Manager · until 31 mars 2015

Ended

At this address

Other companies at this address

Company	CBE no.
PO²● Active	0598.929.369

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	15/06/2026	23/06/2025	04/07/2024	26/07/2023	15/07/2022	09/07/2021
General meeting	12/06/2026	13/06/2025	14/06/2024	09/06/2023	30/06/2022	11/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

20 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	12/06/2026	15/06/2026	French	PDF
Abridged model	31/12/2024	13/06/2025	23/06/2025	French	PDF
Abridged model	31/12/2023	14/06/2024	04/07/2024	French	PDF
Abridged model	31/12/2022	09/06/2023	26/07/2023	French	PDF
Abridged model	31/12/2021	30/06/2022	15/07/2022	French	PDF
Abridged model	31/12/2020	11/06/2021	09/07/2021	French	PDF
Abridged model	31/12/2019	23/06/2020	16/07/2020	French	PDF
Abridged model	31/12/2018	14/06/2019	18/06/2019	French	PDF
Abridged model	31/12/2017	08/06/2018	21/06/2018	French	PDF
Abridged model	31/12/2016	09/06/2017	07/07/2017	French	PDF
Abridged model	31/12/2015	10/06/2016	30/07/2016	French	PDF
Abridged model	31/12/2014	12/06/2015	30/06/2015	French	PDF
Abridged model	31/12/2013	13/06/2014	30/06/2014	French	PDF
Abridged model	31/12/2012	05/08/2013	12/08/2013	French	PDF
Abridged model	31/12/2011	08/06/2012	27/06/2012	French	PDF
Abridged model	31/12/2010	12/08/2011	12/08/2011	French	PDF
Abridged model	31/12/2009	11/06/2010	05/07/2010	French	PDF
Abridged model	31/12/2008	12/06/2009	02/07/2009	French	PDF
Abridged model	31/12/2007	24/06/2008	22/07/2008	French	PDF
Abridged model	31/12/2006	08/06/2007	03/07/2007	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 1 M€ and 2,5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 6 ended

Active mandates

PO²

Director · since 01 avril 2015 · 0598.929.369

Represented by Philippe ROBYN

Active

Ended mandates

PO²

Manager · since 01 avril 2015 · 0598.929.369

Represented by Philippe ROBYN

Ended

PO²

Manager · since 01 avril 2015 · 0598.929.369

Represented by Philippe ROBYN

Ended

Nadine VAN HEMMENS

Manager · since 05 juillet 2005

Ended

Nadine VANHEMMENS

Manager · until 31 mars 2015

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates09/02/2024
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - MODIFICATION FORME JURIDIQUE - DENOMINATION - DEMISSIONS, NOMINATIONS
PDF
Mandates22/04/2015
DEMISSIONS, NOMINATIONS
PDF
Other01/12/2005
DIVERS
PDF
Other15/07/2005
RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025183,7 k €↑
2024
Annual accounts 2024180,2 k €↓
2024
Name changePALISEUL PHARMA
2023
Annual accounts 2023190 k €↑
2022
Annual accounts 2022169,5 k €↑
2021
Annual accounts 2021149,8 k €↓
2020
Annual accounts 2020152,3 k €↑
2019
Annual accounts 2019119,5 k €↓
2018
Annual accounts 2018154,8 k €↑
2017
Annual accounts 2017122,9 k €↓
2016
Annual accounts 2016129 k €↑
2015
Annual accounts 201578 k €↑
2014
Annual accounts 201436,5 k €↑
2013
Annual accounts 201328,9 k €↑
2012
Annual accounts 2012-1,4 k €↓
2011
Annual accounts 20114,2 k €↓
2010
Annual accounts 201012,2 k €↑
2009
Annual accounts 20099,5 k €↑
2008
Annual accounts 2008-9,6 k €↓
2007
Annual accounts 20078,5 k €↑
2006
Annual accounts 2006-774 €
2006
Name changePHARMACIE VANHEMMENS
07/07/2005
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

PALISEUL PHARMA

Overview

What does PALISEUL PHARMA do?

Trend over 20 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline